{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975666",
  "id": "02975666",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwwc2rtwrgv.pdf",
  "summary": "- **R&D Pipeline**: Targets global addressable markets worth >US$8bn; 8 patented products in active R&D, plus 24 off-patent injectables and improved migraine treatment in development.  \n- **FY26 Guidance**: Confirmed operating profit forecast of **A$20\u201324m**; on track for **FY27 revenue target of A$300m**.  \n- **Commercialisation Progress**: 5 advanced R&D programs entering global markets, including Maxigesic\u00ae variants, Crystaderm\u00ae, Micolette\u00ae, Kiwisoothe\u00ae, and capsaicin cream.  \n\n*No material trading or capital markets actions (e.g., raising, dividends) announced. Focus is strategic/growth outlook.*",
  "usage": {
    "prompt_tokens": 1072,
    "completion_tokens": 149,
    "total_tokens": 1221,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:58:39.269991"
}